Obesity drug therapy

Minerva Endocrinologica

Volumn 38, Issue 3, 2013, Pages 245-254

  Baretic M ^a  

^a Internal University Hospital Center   (Croatia)

Author keywords

Drug therapy; Obesity; Obesity, therapy

Indexed keywords

ARISTOLOCHIC ACID; FENFLURAMINE; FLUOXETINE; GLUCAGON LIKE PEPTIDE 1; HERBACEOUS AGENT; INCRETIN; INSULIN; LEPTIN RECEPTOR; MELANOCORTIN; NEUROPEPTIDE Y; PHENTERMINE; RECOMBINANT LEPTIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; USNIC ACID;

ARCUATE NUCLEUS; AREA POSTREMA; BEHAVIOR THERAPY; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BODY MASS; CALORIC INTAKE; CHINESE HERB; CHRONICITY; COMORBIDITY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEFECATION URGENCY; DEPRESSION; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG WITHDRAWAL; ENERGY CONSUMPTION; ENERGY EXPENDITURE; EPILEPSY; EXERCISE; GLYCEMIC INDEX; HEART PALPITATION; HEART RATE; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; HYPOTHALAMUS NUCLEUS; INSOMNIA; INSULIN RELEASE; INSULIN SENSITIVITY; INTERSTITIAL NEPHRITIS; INTESTINE MOTILITY; KNEE OSTEOARTHRITIS; LATERAL HYPOTHALAMUS; LIFESTYLE MODIFICATION; LIPID ABSORPTION; LIPOLYSIS; LONG TERM CARE; LOSS OF APPETITE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHARMACEUTICAL CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; REVIEW; SEDENTARY LIFESTYLE; SIDE EFFECT; STEATORRHEA; STOMACH EMPTYING; STOMACH MOTILITY; SUICIDAL IDEATION; USNEA; VALVULAR HEART DISEASE; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; XEROSTOMIA;

ANTI-OBESITY AGENTS; APPETITE; COMBINED MODALITY THERAPY; COMORBIDITY; COST-BENEFIT ANALYSIS; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DRUG COMBINATIONS; EXERCISE THERAPY; FRUCTOSE; GASTROINTESTINAL HORMONES; HUMANS; INCRETINS; INSULIN; INTESTINES; LACTONES; LEPTIN; LIFE STYLE; MODELS, BIOLOGICAL; NEUROPEPTIDES; OBESITY; PHENTERMINE; PHYTOTHERAPY; PIPERIDINES; PLANT PREPARATIONS; PYRAZOLES;

EID: 84890212884     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Baretić M, Balić S. Overweight and obesity in Croatia. Diabetol Croat 2002;31:105-12. (Pubitemid 36164161)
2. Obesity and overweight, Fact sheet N. 311, 2012. [cited 2013 May 14]. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/
3. Lee IM, Blair SN, Allison DB, Folsom AR, Harris TB, Manson JE et al. Epidemiologic data on the relationships of caloric intake, energy balance, and weight gain over the life span with longevity and morbidity. J Gerontol A Biol Sci Med Sci 2001;56:7-19.
4. Collins JK. Methodology for the objective measurement of body image. Int J Eat Disorder 1987;6:393-9. (Pubitemid 17108910)
5. O'Conner J, Dorwick PW. Cognitions in normal weight, overweight and previously overweight adults. Cogint Ther Res 1987;11:315-26. (Pubitemid 17129335)
6. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among U.S. children, adolescents, and adults, 1999-2002. JAMA 2004;291:2847-50. (Pubitemid 38747805)
7. [No authors listed]. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998;158:1855-67.
8. Brown T, Avenell A, Edmunds LD, Moore H, Whittaker V, Avery L et al. Systematic review of long-term lifestyle interventions to prevent weight gain and morbidity in adults. Obes Rev 2009;627-38.
9. Global Status Report on Noncommunicable Diseases 2010 WHO Headquarters, [cited 2013 May 14], Available at: http://www.who.int/nmh/publications/ncd- report-full-en.pdf
10. National Center for Health Statistics. Health, United States, 2011: With Special Feature on Socioeconomic Status and Health. Hyattsville, MD. 2012. [cited 2013 May 14]. Available at: http://www.cdc.gov/nchs/data/hus/hus11. pdf#069
11. Global Prevalence of Adult Obesity IASO. [cited 2013 May 14]. Available at: http://www.iaso.org/.../Global-Prevalence-of-Adult-ObesityMay-2010-revised- with-headings.pdf/
12. Obesity guidance on the prevention, identification,assessment and management of overweight and obesity in adults and children. NICE clinical guideline 43. [cited 2013 May 14]. Available at: www.nice.org.uk/CG04
13. Bray GA. Use and abuse of appetite suppressant drugs in the treatment of obesity. Ann Intern Med 1993;119:707-13. (Pubitemid 23313694)
14. Jelčić J, Baretić M, Koršić M. 4th guidelines on diagnosis and treatment of obesity. Lijec Vjesn 2010;132:269-71.
15. Chaput JP, Tremblay A. The glucostatic theory of appetite control and the risk of obesity and diabetes. Int J Obes 2009;33:46-53.
16. Ramirez I. Does dietary hyperphagia contradict the lipostatic theory? Neurosci Biobehav Rev 1990;14:117-23. (Pubitemid 20159548)
17. Ahim RS. Central actions of adipocyte hormones. Trends Endocrinol Metab 2005;16:307-13.
18. Steinberg GR, Parolin ML, Heigenhauser GJ, Dyck DJ. Leptin increases FA oxidation in lean but not obese human skeletal muscle: evidence of peripheral leptin resistance. Am J Physiol Endocrinol Metab 2002;283:187-92.
19. Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319-36. (Pubitemid 34177884)
20. Vatier C, Gautier JF, Vigouroux C. Therapeutic use of recombinant methionyl human leptin. Biochimie 2012;94:2116-25.
21. Tam CS, Lecoultre V, Ravussin E. Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther 2011;11:1677-85.
22. N Finer. Sibutramine: its mode of action and efficacy. International Journal of Obesity 2002;26:29-33.
23. Hansen DL, Toubro S, Stock MJ, Macdonald LA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999;23:1016-24. (Pubitemid 29476203)
24. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss. Arch Intern Med 2004;164:994-1003. (Pubitemid 38581520)
25. From JWPT, Astrup A, Finer N. Effect of sibutramine on weight maintenance after weight loss: a randomized trail. STORM study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25.
26. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363.905-17.
27. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy 11th and safety of the weight-loss drug rimonabant: a meta analysis of randomized trials. Lancet 2007;370:1706-13. (Pubitemid 350100788)
28. Wise S: Clinical studies with fluoxetine in obesity. Am J Clin Nutr 1992;55:181-4.
29. Heck A, Yanovski J, Calis J. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000;20:270-9. (Pubitemid 30140745)
30. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61. (Pubitemid 38196725)
31. Damci T, Yalin S, Balci H, Osar Z, Korugan U, Ozyazar M et al. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 2004;27:1077-80. (Pubitemid 38579769)
32. Moore B, Edie ES, Abram JH. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem 1906;1:28-38.
33. Creutzfeldt W. The [pre-] history of the incretin concept. Regul peptic 2005;128:87-91.
34. Creutzfeldt W. The incretin concept today. Diabetologia 1979;16:75-85. (Pubitemid 9231263)
35. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R et al. Incretin effects of glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492-8. (Pubitemid 16035703)
36. Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975;1:14-6.
37. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-52.
38. Gutzwiller JP, Göke B, Drewe J. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999;44:81-6. (Pubitemid 29143284)
39. Or̈skov C, Poulsen SS, Moller M. GLP-1 receptors in the subfornical organ and the area postrema are accessible to circulation glucagon-like peptide 1. Diabetes 1996;45:832-5.
40. Russell-Jones D, Gough S. Recent advances in incretin-based therapies. Clin Endocrinol 2012;77:489-99.
41. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ 2013;24;3;e001986.
42. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin. Diabetes Care 2010;33:2349-54.
43. Refusal of the marketing authorization for Qsiva (phentermine/topiramate) . Outcome of re-examination. [cited 2013 May 14]. Available at: http.//www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion--- Initial-authorisation/human/002350/WC500139215.pdf
44. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012,95:297-308.
45. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet 2011;16:1341-52.
46. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004;8:1-182.
47. Ara R, Blake L, Gray L, Hernández M, Crowther M, Dunkley A et al. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technol Assess 2012;16:1-195.
48. Neovius M, Narbro K. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. Int J Obes 2008;32:1752-63.
49. Chan TY. Potential risks associated with the use of herbal anti-obesity products. Drug Saf 2009;32:453-6.
50. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387-91. (Pubitemid 23048140)
51. Hsu LM, Huang YS, Chang FY, Lee SD. 'Fat burner' herb, induced acute hepatitis in a family. J Gastroenterol Hepatol 2005;20:1138-9.